SubHero Banner

Sandoz – Recall of Losartan/Hydrochlorothiazide

November 8, 2018 - Sandoz announced a voluntary, consumer-level recall of one lot of losartan/hydrochlorothiazide (HCTZ) tablets due to the detection of trace amounts of an unexpected impurity, identified as n-nitrosodiethylamine (NDEA) contained in the active pharmaceutical ingredient (API) losartan, manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd.

Download PDF